Retatrutide early access now exists, but it isn't a general way to get the drug before approval. Lilly's program is for a small group of adults with severe obesity and serious complications who have exhausted standard options and cannot join a suitable clinical trial. A treating clinician has to make the request. A patient cannot order retatrutide through the program or apply alone.
That distinction matters. Retatrutide has not been approved by any regulatory agency, and it isn't commercially available. Expanded access creates a possible exception for one patient at a time; it does not open a retail prescription lane.
Retatrutide early access changed in August
On August 3, Lilly confirmed that it was reviewing requests from health care providers. The official program is called single-patient expanded access, sometimes known as compassionate use: it lets a person with a serious condition receive an investigational drug outside a trial when satisfactory options have run out.
As of September 9, 2026, the day this article was written, the ClinicalTrials.gov record for NCT07629401 was marked "Available" after an August 6 update, following Lilly's August 3 confirmation. Lilly's July 23 company release says it plans to submit retatrutide to the FDA in the first quarter of 2027, not in 2026. On August 24, an FDA warning letter also identified retatrutide sold online by a peptide seller as an unapproved drug.
The trial research explains the interest, but it does not widen the doorway. A phase 2 obesity trial published in The New England Journal of Medicine in 2023 enrolled 338 adults, while TRANSCEND-T2D-1, a phase 3 diabetes trial published in The Lancet in 2026, enrolled 537 adults with type 2 diabetes. Both studied selected groups under a protocol, meaning a fixed research plan with close monitoring. Neither study turned retatrutide into a medicine for public sale.
Who the program is actually for
The registry lists five requirements. All five have to apply:
- The person is at least 18.
- Their BMI, a height-to-weight screening number, is 35 or higher despite following and tolerating the highest available dose of an approved chronic weight-management treatment. The record calls this refractory obesity, meaning it has not responded adequately to the best available treatment.
- They have at least two serious or life-threatening obesity-related complications and already receive standard care for them.
- They cannot join an ongoing retatrutide trial or a similar investigational trial because they do not meet its criteria or no enrolling site is reasonably accessible.
- They have discussed every standard option, including bariatric surgery, through shared decision-making with their clinician.
The record gives one exclusion: a medical reason that makes retatrutide unsuitable. It also says access depends on geography, supply, and an individual eligibility review. Meeting the checklist therefore makes a request possible; it does not promise access.
Why a doctor has to submit the request
This pathway makes the treating clinician responsible for more than writing a prescription. The clinician first asks Lilly to supply the investigational drug. If Lilly agrees, the clinician submits an individual-patient investigational new drug application, or IND, to the FDA and agrees to oversee treatment and safety reporting.
The FDA's physician guide says non-emergency treatment also needs review by an institutional review board, an independent group that protects patients in research-related care, plus informed consent. FDA says it allows more than 99% of the completed single-patient requests it receives to proceed. That figure does not mean 99% of people who ask Lilly get the drug: the manufacturer has to agree before an application reaches FDA.
This is why a form sold by an online middleman is not the program. The request starts inside an existing clinical relationship with the doctor managing the serious complications.
What the program does not change
Expanded access is not approval. It does not establish a public price, create routine pharmacy stock, or guarantee that a request will be accepted. Lilly's retatrutide explainer, last updated in July, says the drug is not available for public use. The newer access record carves out a narrow exception; it does not erase that answer for almost everyone.
It also does not create a compounding route. The FDA's current GLP-1 page says retatrutide does not qualify for compounding under federal law because it is not a component of an approved drug and has not been found safe and effective for any condition. A vial advertised online under the retatrutide name is not the Lilly trial supply and is not expanded access.
Why an online vial is a different proposition
The expanded-access drug comes from the developer, through a named treating clinician, with consent, monitoring, and a reporting trail. An online vial arrives outside that chain. Its label cannot prove that the vial contains the same molecule, the stated amount, or a sterile preparation.
The FDA's August 24 letters are covered in our report on the peptide warning-letter action. The separate retatrutide lawsuit timeline follows Lilly's cases against sellers. Those stories concern the online market; they do not broaden the eligibility rules for the genuine program.
That is the practical value of a pharmacy of record for medications that can lawfully be prescribed: a labeled product, traceable lot, accountable prescriber, and a clear place to report a problem. Those safeguards cannot turn an investigational molecule into an available prescription, but they do separate medical care from an anonymous sale.
What a provider can discuss today
For readers looking for a treatment available now, tirzepatide and semaglutide are the relevant conversations. They are not retatrutide. The tirzepatide and retatrutide comparison covers the difference, while our retatrutide overview owns the molecule's mechanism and trial results.
Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved. A licensed provider may still prescribe one of these compounded formulations when medically appropriate; that decision is between the patient and the doctor.
A licensed provider reviews every Promise request and not everyone qualifies. The review is for the medication that can actually be prescribed, not an application to Lilly's retatrutide program.
What to watch next
A submission planned for early 2027 is the next regulatory step, not a promised approval date. After Lilly submits, the FDA still has to review the evidence and decide. Until then, the useful signals are changes to the NCT07629401 status, any revision to its eligibility language, and an actual FDA decision after a filing.
The calm answer is also the honest one: early access is real, but it is designed for exceptional medical need. For everyone else, the choice today is between waiting and discussing currently prescribable options with a clinician.
If a currently available option is the question, a consultation can sort out whether it fits the person's history without pretending it is retatrutide.